{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:39:34Z","timestamp":1792687174656,"version":"4.5.0"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuromuscular Disorders"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.nmd.2026.107451","type":"journal-article","created":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T06:50:02Z","timestamp":1791183002000},"page":"107451","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Twenty years of givinostat in Duchenne muscular dystrophy: a patient-organisation perspective"],"prefix":"10.1016","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1704-0143","authenticated-orcid":false,"given":"Filippo","family":"Buccella","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Furlong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nmd.2026.107451_bib0001","unstructured":"Agenzia Italiana del Farmaco. Determina AIFA n. Pres. 357-2026 del 19 marzo 2026 \u2014 DUVYZAT (givinostat). Available at: https:\/\/www.aifa.gov.it\/-\/attivazione-web-e-pubblicazione-schede-di-monitoraggio-registro-duvyzat [accessed 29 September 2026]."},{"key":"10.1016\/j.nmd.2026.107451_bib0002","unstructured":"U.S. Food and Drug Administration. FDA approves nonsteroidal treatment for Duchenne muscular dystrophy. Press release, 21 March 2024. Available at: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-nonsteroidal-treatment-duchenne-muscular-dystrophy [accessed 29 September 2026]."},{"key":"10.1016\/j.nmd.2026.107451_bib0003","unstructured":"European Medicines Agency. Duvyzat (givinostat): conditional marketing authorisation valid throughout the EU, 6 June 2025. European Public Assessment Report. Available at: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/duvyzat [accessed 29 September 2026]."},{"issue":"4","key":"10.1016\/j.nmd.2026.107451_bib0004","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/S1097-2765(01)00373-2","article-title":"Class I histone deacetylases sequentially interact with MyoD and pRb during skeletal myogenesis","volume":"8","author":"Puri","year":"2001","journal-title":"Mol Cell"},{"issue":"11","key":"10.1016\/j.nmd.2026.107451_bib0005","doi-asserted-by":"crossref","first-page":"7757","DOI":"10.1073\/pnas.112218599","article-title":"Stage-specific modulation of skeletal myogenesis by inhibitors of nuclear deacetylases","volume":"99","author":"Iezzi","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"issue":"10","key":"10.1016\/j.nmd.2026.107451_bib0006","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/nm1479","article-title":"Functional and morphological recovery of dystrophic muscles in mice treated with deacetylase inhibitors","volume":"12","author":"Minetti","year":"2006","journal-title":"Nat Med"},{"issue":"49","key":"10.1016\/j.nmd.2026.107451_bib0007","doi-asserted-by":"crossref","first-page":"19183","DOI":"10.1073\/pnas.0805514105","article-title":"HDAC2 blockade by nitric oxide and histone deacetylase inhibitors reveals a common target in Duchenne muscular dystrophy treatment","volume":"105","author":"Colussi","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"10.1016\/j.nmd.2026.107451_bib0008","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2119\/molmed.2013.00011","article-title":"Preclinical studies in the mdx mouse model of Duchenne muscular dystrophy with the histone deacetylase inhibitor givinostat","volume":"19","author":"Consalvi","year":"2013","journal-title":"Mol Med"},{"issue":"4","key":"10.1016\/j.nmd.2026.107451_bib0009","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1002\/emmm.201202096","article-title":"Fibroadipogenic progenitors mediate the ability of HDAC inhibitors to promote regeneration in dystrophic muscles of young, but not old mdx mice","volume":"5","author":"Mozzetta","year":"2013","journal-title":"EMBO Mol Med"},{"issue":"8","key":"10.1016\/j.nmd.2026.107451_bib0010","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1101\/gad.234468.113","article-title":"HDAC-regulated myomiRs control BAF60 variant exchange and direct the functional phenotype of fibro-adipogenic progenitors in dystrophic muscles","volume":"28","author":"Saccone","year":"2014","journal-title":"Genes Dev"},{"issue":"9","key":"10.1016\/j.nmd.2026.107451_bib0011","doi-asserted-by":"crossref","DOI":"10.15252\/embr.202050863","article-title":"HDAC inhibitors tune miRNAs in extracellular vesicles of dystrophic muscle-resident mesenchymal cells","volume":"21","author":"Sandon\u00e0","year":"2020","journal-title":"EMBO Rep"},{"issue":"6","key":"10.1016\/j.nmd.2026.107451_bib0012","doi-asserted-by":"crossref","DOI":"10.15252\/embr.202254721","article-title":"Determinants of epigenetic resistance to HDAC inhibitors in dystrophic fibro-adipogenic progenitors","volume":"23","author":"Consalvi","year":"2022","journal-title":"EMBO Rep"},{"issue":"3","key":"10.1016\/j.nmd.2026.107451_bib0013","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.molmed.2024.01.007","article-title":"HDAC inhibitors as pharmacological treatment for Duchenne muscular dystrophy: a discovery journey from bench to patients","volume":"30","author":"Mozzetta","year":"2024","journal-title":"Trends Mol Med"},{"issue":"1","key":"10.1016\/j.nmd.2026.107451_bib0014","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1474-4422(09)70271-6","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management","volume":"9","author":"Bushby","year":"2010","journal-title":"Lancet Neurol"},{"issue":"3","key":"10.1016\/j.nmd.2026.107451_bib0015","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S1474-4422(18)30024-3","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management","volume":"17","author":"Birnkrant","year":"2018","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1016\/j.nmd.2026.107451_bib0016","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.nmd.2014.09.003","article-title":"Measuring clinical effectiveness of medicinal products for the treatment of Duchenne muscular dystrophy","volume":"25","author":"Lynn","year":"2015","journal-title":"Neuromuscul Disord"},{"issue":"10","key":"10.1016\/j.nmd.2026.107451_bib0018","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.nmd.2016.07.002","article-title":"Histological effects of givinostat in boys with Duchenne muscular dystrophy","volume":"26","author":"Bettica","year":"2016","journal-title":"Neuromuscul Disord"},{"issue":"4","key":"10.1016\/j.nmd.2026.107451_bib0019","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S1474-4422(24)00036-X","article-title":"Safety and efficacy of givinostat in boys with Duchenne muscular dystrophy (EPIDYS): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"23","author":"Mercuri","year":"2024","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.nmd.2026.107451_bib0020","unstructured":"ClinicalTrials.gov. Clinical study to evaluate the efficacy and safety of givinostat in ambulant patients with Becker muscular dystrophy (NCT03238235). Sponsor: Italfarmaco S.p.A. Study start: 9 January 2018. Available at: https:\/\/clinicaltrials.gov\/study\/NCT03238235 [accessed 29 September 2026]."}],"container-title":["Neuromuscular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896626011193?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896626011193?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:01:24Z","timestamp":1792684884000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960896626011193"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":19,"alternative-id":["S0960896626011193"],"URL":"https:\/\/doi.org\/10.1016\/j.nmd.2026.107451","relation":{},"ISSN":["0960-8966"],"issn-type":[{"value":"0960-8966","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Twenty years of givinostat in Duchenne muscular dystrophy: a patient-organisation perspective","name":"articletitle","label":"Article Title"},{"value":"Neuromuscular Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmd.2026.107451","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107451"}}